Prognostic analysis of children with Henoch-Schonlein purpura treated by Helicobacter pylori eradication therapy

CAI Hua-Bo; LI Yong-Bai; ZHAO Hui; ZHOU Shao-Ming; ZHAO Xiao-Dong

doi:10.7499/j.issn.1008-8830.2014.03.003

PDF(1091 KB)

Chinese Journal of Contemporary Pediatrics ›› 2014, Vol. 16 ›› Issue (3) : 234-237. DOI: 10.7499/j.issn.1008-8830.2014.03.003

TOPIC OF DIGESTIVE DISEASES

Prognostic analysis of children with Henoch-Schonlein purpura treated by Helicobacter pylori eradication therapy

CAI Hua-Bo¹, LI Yong-Bai¹, ZHAO Hui¹, ZHOU Shao-Ming¹, ZHAO Xiao-Dong²

Author information +

History +

Abstract

Objective To investigate the effect of Helicobacter pylori (Hp) eradication therapy on prognosis in children with Henoch-Schonlein purpura (HSP). Methods A total of 153 children with HSP were divided into Hp infection treatment group (n=22), Hp infection control group (n=21), and Hp infection-negative group (n=110). The Hp infection treatment group received one-week triple therapy for Hp eradication in addition to conventional treatment, while the Hp infection control group and Hp infection-negative group received conventional treatment. All patients were followed up for prognostic evaluation. Results The response rates of the Hp infection treatment, control, and negative groups were 86% (19/22), 90% (19/21) and 85% (94/110), respectively (P>0.05). The recurrence rates of HSP in the Hp infection treatment, control, and negative groups were 14% (3/22), 24% (5/21) and 31% (34/110), respectively (P>0.05). The incidence of Henoch-Schonlein purpura nephritis (HSPN) in the Hp infection-negative group (36%, 40/110) and control group (33%, 7/21) was significantly higher than that in the Hp infection treatment group (5%, 1/22) (P<0.05 for both), but no significant difference in the incidence of HSPN was found between the control and negative groups (P>0.05). Conclusions One-week triple therapy for Hp eradication may be useful to reduce the incidence of HSPN in children with HSP infected with Hp.

Key words

Henoch-Schonlein purpura / Helicobacter pylori / Eradication therapy / Prognosis / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

CAI Hua-Bo, LI Yong-Bai, ZHAO Hui, ZHOU Shao-Ming, ZHAO Xiao-Dong. Prognostic analysis of children with Henoch-Schonlein purpura treated by Helicobacter pylori eradication therapy[J]. Chinese Journal of Contemporary Pediatrics. 2014, 16(3): 234-237 https://doi.org/10.7499/j.issn.1008-8830.2014.03.003

References

[1] Gonzalez LM, Janniger CK, Schwartz RA. Pediatric Henoch-Schonlein purpura[J]. Int J Dermatol, 2009, 48(11): 1157-1165.
[2] 李克莉, 刘大卫, 武文娣, 等. 中国六个市2007-2009 年过敏性紫癜住院病例发病情况分析[J]. 中国疫苗和免疫, 2011, 17(2): 128-132.
[3] Xiong LJ, Tong Y, Wang ZL, et al. Is Helicobacter pylori infection associated with Henoch-Schonlein purpura in Chinese children-a meta-analysis[J]. World J Pediatr, 2012, 8(4): 301-308.
[4] 蔡华波, 李永柏, 赵晓东. 儿童幽门螺杆菌与过敏性紫癜致病相关性[J]. 中国实用儿科杂志, 2013, 28(2): 102-105.
[5] Ozen S, Ruperto N, Dillon ML, et al. EULAR/PReS endorsed c o n s e n s u s c r i t e n a f o r t h e c l a s s i f i c a t i o n o f c h i l d h o o d vasculitldes[J]. Ann Rheum Dis, 2006, 65(7): 936-941.
[6] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌研究协作组. 第四次全国幽门螺杆菌感染处理共识报告[J]. 中华内科杂志, 2012, 51(10): 832-837.
[7] 胡亚美, 江载芳. 诸福棠实用儿科学[M]. 第7 版. 北京: 人民卫生出版社, 2002: 688-690.
[8] Mehri N, kambiz E, Ahmad K, et al. The efficacy of a 1-week triple therapy for eradication of Helicobacter pylori infection in children[J]. Arab J Gastroenterol, 2011, 12(1): 37-39.
[9] 莱杜万, 季红, 刘玲, 等. 幽门螺杆菌与儿童过敏性紫癜的关系[J]. 吉林医学, 2013, 34(12): 2214-2215.
[10] 中华医学会儿科学分会肾脏病学组. 儿童常见肾脏疾病诊治循证指南(二): 紫癜性肾炎的诊治循证指南(试行)[J]. 中华儿科杂志, 2009, 47(12): 911-913.
[11] 胡伏莲. 幽门螺杆菌致病因子与胃黏膜屏障[J]. 临床药物治疗杂志, 2007, 5(1): 1-4.
[12] Franceschi F, Sepulveda AR, Gasbarrin IA, et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigengs: possible pathogenic link between Helicobacter pylori infection and atherosclerosis[J]. Circulation, 2002, 106(4): 430-434.
[13] Lenzi C, Palazzuoli A, Giordano N, et al. H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease[J]. World J Gastroenterol, 2006, 12(48): 7815-7820.
[14] Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection[J]. Helicopter, 2010, 15 suppl 1: 14-20.
[15] Li YY, Li CR, Wang GB, et al. Investigation of the change in CD4⁺ T cell subset in children with Henoch-Schonlein purpura[J]. Rheumatol Int, 2011, 32(12): 3785-3792.
[16] Shin JI, Koh H, Lee JS. Henolein-Schonlein purpura associated with helicobacter pylori infection: the pathogenic roles of IgA, C3, and cryoglobulins?[J]. Pediatr Dermatol, 2009, 26(6): 768-769.
[17] Shin JI, Park JM, Shin YH, et al. Serum IgA/C3 ratio may be a useful marker of disease activity in severe Henoch-Schonlein nephritis[J]. Nephron Clin Pract, 2005, 101(2): c72-c78.
[18] 赖冬波, 王嘉怡, 何丽雅, 等. 幽门螺杆菌感染对过敏性紫癜患儿肾损害的影响[J]. 实用儿科临床杂志, 2008, 23(9): 684-685.
[19] Li Q, Lin X, Wu Z, et al. Immuno-histochemistry analysis of Helicobacter pylori antigen in renal biopsy specimens from patients with glomerulonephritis[J]. Saudi J Kidney Dis Transpl, 2013, 24(4): 751-758.
[20] 世界胃肠病学组织. 世界胃肠病学组织(WGO-OMGE)临床指南—发展中国家幽门螺杆菌感染[J]. 胃肠病学, 2007, 12(1): 40-52.
[21] 江米足. 儿童消化系统疾病临床研究进展[J]. 中国实用儿科杂志, 2009, 24(5): 342-346.
[22] 胡伏莲. 幽门螺杆菌感染与上胃肠道疾病[J]. 中国医刊, 2007, 42(2):19-22.
[23] Soler MJ, Mir M, Rodriguez E, et al. Recurrence of IgA nephropathy and Henoch-Schonlein purpura after kidney transplantion: risk factors and graft survival[J]. Transplantation Proc, 2005, 37(9): 3705-3709.